AtriCure (NASDAQ:ATRC) Sets New 1-Year High – Here’s What Happened

AtriCure, Inc. (NASDAQ:ATRC)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $44.80 and last traded at $44.6980, with a volume of 51505 shares. The stock had previously closed at $44.30.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ATRC shares. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday, July 28th. UBS Group dropped their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Canaccord Genuity Group boosted their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.50.

AtriCure Price Performance

The stock has a 50 day moving average of $34.64 and a two-hundred day moving average of $31.57. The stock has a market cap of $2.33 billion, a PE ratio of 217.92 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same period in the prior year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current year.

Insider Transactions at AtriCure

In other news, insider Vinayak Doraiswamy sold 6,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the sale, the insider owned 86,511 shares in the company, valued at $3,363,547.68. This represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Maggie Yuen sold 3,500 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the sale, the director owned 14,015 shares of the company’s stock, valued at $538,456.30. The trade was a 19.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 44,246 shares of company stock worth $1,691,895. 4.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. acquired a new stake in AtriCure during the 2nd quarter worth about $37,000. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure in the 2nd quarter valued at about $40,000. Allworth Financial LP acquired a new position in shares of AtriCure in the 2nd quarter valued at about $43,000. Smartleaf Asset Management LLC lifted its position in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares in the last quarter. Finally, Fifth Third Bancorp purchased a new stake in shares of AtriCure in the first quarter worth approximately $51,000. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.